AU2003253350B2 - Use of alkyl phosphocholines in combination with antitumor medicaments - Google Patents

Use of alkyl phosphocholines in combination with antitumor medicaments Download PDF

Info

Publication number
AU2003253350B2
AU2003253350B2 AU2003253350A AU2003253350A AU2003253350B2 AU 2003253350 B2 AU2003253350 B2 AU 2003253350B2 AU 2003253350 A AU2003253350 A AU 2003253350A AU 2003253350 A AU2003253350 A AU 2003253350A AU 2003253350 B2 AU2003253350 B2 AU 2003253350B2
Authority
AU
Australia
Prior art keywords
treatment
combination
benign
oxaliplatin
fludarabine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003253350A
Other languages
English (en)
Other versions
AU2003253350A1 (en
Inventor
Jurgen Engel
Eckhard Gunther
Herbert Sindermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeterna Zentaris GmbH
Original Assignee
Aeterna Zentaris GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeterna Zentaris GmbH filed Critical Aeterna Zentaris GmbH
Publication of AU2003253350A1 publication Critical patent/AU2003253350A1/en
Application granted granted Critical
Publication of AU2003253350B2 publication Critical patent/AU2003253350B2/en
Priority to AU2008203060A priority Critical patent/AU2008203060B2/en
Assigned to AETERNA ZENTARIS GMBH reassignment AETERNA ZENTARIS GMBH Request to Amend Deed and Register Assignors: ZENTARIS GMBH
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2003253350A 2002-07-30 2003-07-29 Use of alkyl phosphocholines in combination with antitumor medicaments Ceased AU2003253350B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2008203060A AU2008203060B2 (en) 2002-07-30 2008-07-10 Use of alkyl phosphocholines in combination with antitumor medicaments

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39961502P 2002-07-30 2002-07-30
US60/399,615 2002-07-30
PCT/EP2003/008346 WO2004012744A1 (de) 2002-07-30 2003-07-29 Anwendung von alkylphosphocholinen in kombination mit antitumormedikamenten

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2008203060A Division AU2008203060B2 (en) 2002-07-30 2008-07-10 Use of alkyl phosphocholines in combination with antitumor medicaments

Publications (2)

Publication Number Publication Date
AU2003253350A1 AU2003253350A1 (en) 2004-02-23
AU2003253350B2 true AU2003253350B2 (en) 2008-06-26

Family

ID=31495746

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2003253350A Ceased AU2003253350B2 (en) 2002-07-30 2003-07-29 Use of alkyl phosphocholines in combination with antitumor medicaments
AU2008203060A Ceased AU2008203060B2 (en) 2002-07-30 2008-07-10 Use of alkyl phosphocholines in combination with antitumor medicaments

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2008203060A Ceased AU2008203060B2 (en) 2002-07-30 2008-07-10 Use of alkyl phosphocholines in combination with antitumor medicaments

Country Status (26)

Country Link
US (3) US8389497B2 (enExample)
EP (2) EP1545553B1 (enExample)
JP (1) JP2005535688A (enExample)
KR (3) KR101066804B1 (enExample)
CN (1) CN1302780C (enExample)
AR (1) AR040717A1 (enExample)
AT (1) ATE516036T1 (enExample)
AU (2) AU2003253350B2 (enExample)
BR (1) BR0313048A (enExample)
CA (1) CA2493023C (enExample)
CY (1) CY1111902T1 (enExample)
DK (1) DK1545553T3 (enExample)
ES (1) ES2369535T3 (enExample)
HR (1) HRP20050184B1 (enExample)
IL (1) IL166329A (enExample)
MX (1) MXPA05001203A (enExample)
NO (1) NO335196B1 (enExample)
NZ (1) NZ538428A (enExample)
PL (1) PL375493A1 (enExample)
PT (1) PT1545553E (enExample)
RU (1) RU2005105693A (enExample)
SI (1) SI1545553T1 (enExample)
TW (1) TWI332007B (enExample)
UA (1) UA82322C2 (enExample)
WO (1) WO2004012744A1 (enExample)
ZA (1) ZA200500453B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8383605B2 (en) 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
TWI332007B (en) 2002-07-30 2010-10-21 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antitumor medicaments for the treatment of benign and malignant oncoses in humans and animals
DE10324911B4 (de) 2003-05-30 2005-08-18 Siemens Ag Röntgenvorrichtung mit partiellem digitalem Detektor und Verfahren zum Betrieb einer solchen
WO2006081452A2 (en) * 2005-01-28 2006-08-03 Robert Birch Co-administration of perifosine with chemotherapeutics
WO2009018233A1 (en) * 2007-07-30 2009-02-05 Ardea Biosciences, Inc. Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same
JP5232009B2 (ja) * 2005-12-19 2013-07-10 エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング 低減された細胞毒性を有するアルキルリン脂質誘導体並びにそれらの使用
EP1800684A1 (en) * 2005-12-20 2007-06-27 Zentaris GmbH Novel alkyl phospholipid derivatives and uses thereof
CN101340918B (zh) * 2005-12-19 2012-10-03 阿特纳赞塔里斯有限公司 具有降低细胞毒性的新烷基磷脂衍生物及其用途
US8703179B2 (en) 2006-05-11 2014-04-22 Kimberly-Clark Worldwide, Inc. Mucosal formulation
MX2011006167A (es) * 2008-12-11 2011-07-28 Abraxis Bioscience Llc Combinaciones y modos de administracion de agentes terapeuticos y terapia de combinacion.
MX2011011596A (es) 2010-03-31 2012-02-01 Keryx Biopharmaceuticals Inc Perifosina y capecitabina como un tratamiento combinado para cancer.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59205998D1 (de) * 1991-07-04 1996-05-23 Asta Medica Ag Arzneimittel mit antineoplastischer Wirkung enthaltend als Wirkstoff Octadecyl-[2-(N-methylpiperidino)-ethyl]-phosphat und Verfahren zu dessen Herstellung
US5942639A (en) * 1991-07-04 1999-08-24 Asta Medica Aktiengesellschaft Process for the preparation of alkylphosphocholines and the production thereof in pure form
US6172050B1 (en) * 1992-07-11 2001-01-09 Asta Medica Aktiengesellschaft Phospholipid derivatives
JP3079993B2 (ja) * 1996-03-27 2000-08-21 日本電気株式会社 真空マイクロデバイスおよびその製造方法
DE19650778C2 (de) * 1996-12-06 2001-01-04 Asta Medica Ag Verwendung von Dopaminrezeptor-Antagonisten in der palliativen Tumortherapie
PL189654B1 (pl) * 1998-01-22 2005-09-30 Zentaris Gmbh Zastosowanie miltefosyny do wytwarzania leków
PT1135193E (pt) * 1998-12-04 2003-01-31 Max Delbrueck Centrum Agentes para o tratamento de tumores a base de lipossomas e compreendendo tamoxifeno
CA2356736A1 (en) * 1998-12-21 2000-06-29 Inkeysa. S.A. Use of etherlysophospholipids as antiinflammatory agents
EP2762140B1 (en) * 2001-02-19 2017-03-22 Novartis AG Treatment of solid brain tumours with a rapamycin derivative
PL365285A1 (en) * 2001-03-23 2004-12-27 Shire Biochem Inc. Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs
WO2003005522A1 (es) 2001-07-04 2003-01-16 Acuna Arturo Tapones para sellado de ductos para redes electricas, telefonicas y de fibra optica.
US20060084612A1 (en) * 2002-01-02 2006-04-20 Geroni Maria C Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors
TWI332007B (en) 2002-07-30 2010-10-21 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antitumor medicaments for the treatment of benign and malignant oncoses in humans and animals
WO2005000318A2 (en) * 2003-06-23 2005-01-06 Neopharm, Inc. Method of inducing apoptosis and inhibiting cardiolipin synthesis
WO2006081452A2 (en) 2005-01-28 2006-08-03 Robert Birch Co-administration of perifosine with chemotherapeutics
CN101340918B (zh) * 2005-12-19 2012-10-03 阿特纳赞塔里斯有限公司 具有降低细胞毒性的新烷基磷脂衍生物及其用途
MX2011011596A (es) * 2010-03-31 2012-02-01 Keryx Biopharmaceuticals Inc Perifosina y capecitabina como un tratamiento combinado para cancer.

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Hilgard et al. Advances in Experimental Medicine and Biology (1996) vol. 416 pages 157-164 *
Spruss et al. Journal of Cancer Research (1993) vol. 119 no. 3 pages 142-149 *
Stekar et al. European Journal of Cancer (1995) vol. 31A, no. 3 pages 372-374 *

Also Published As

Publication number Publication date
HRP20050184A2 (en) 2005-04-30
PL375493A1 (en) 2005-11-28
DK1545553T3 (da) 2011-09-12
US8389497B2 (en) 2013-03-05
JP2005535688A (ja) 2005-11-24
IL166329A0 (en) 2006-01-15
NO20051040L (no) 2005-02-25
US8507710B2 (en) 2013-08-13
IL166329A (en) 2012-08-30
US20100190738A1 (en) 2010-07-29
KR20130016413A (ko) 2013-02-14
TWI332007B (en) 2010-10-21
CY1111902T1 (el) 2015-11-04
EP1545553A1 (de) 2005-06-29
US20100189784A1 (en) 2010-07-29
CN1302780C (zh) 2007-03-07
SI1545553T1 (sl) 2011-09-30
HRP20050184B1 (hr) 2014-04-11
KR20110102485A (ko) 2011-09-16
US8551977B2 (en) 2013-10-08
RU2005105693A (ru) 2005-07-10
KR101066804B1 (ko) 2011-09-22
CA2493023A1 (en) 2004-02-12
ATE516036T1 (de) 2011-07-15
NO335196B1 (no) 2014-10-20
PT1545553E (pt) 2011-09-12
WO2004012744A1 (de) 2004-02-12
ZA200500453B (en) 2005-08-31
KR20050026028A (ko) 2005-03-14
EP2301551A1 (de) 2011-03-30
TW200404073A (en) 2004-03-16
MXPA05001203A (es) 2005-06-08
BR0313048A (pt) 2005-06-14
CN1671397A (zh) 2005-09-21
CA2493023C (en) 2012-01-31
NZ538428A (en) 2006-09-29
AR040717A1 (es) 2005-04-20
EP1545553B1 (de) 2011-07-13
AU2008203060B2 (en) 2011-04-21
ES2369535T3 (es) 2011-12-01
AU2003253350A1 (en) 2004-02-23
HK1080751A1 (en) 2006-05-04
US20040097470A1 (en) 2004-05-20
AU2008203060A1 (en) 2008-07-31
UA82322C2 (uk) 2008-04-10

Similar Documents

Publication Publication Date Title
AU2008203060B2 (en) Use of alkyl phosphocholines in combination with antitumor medicaments
EP0828500B1 (en) Use of flavanolignanes for the preparation of medicaments with antiproliferative activity in uterus, ovary and breast
AU2014251087B2 (en) Formulations of oxabicycloheptanes and oxabicycloheptenes
RU2671488C2 (ru) Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака
JP2005501825A (ja) エポシロンを含有する組合せ剤およびその医薬上の使用
AU2011204918B2 (en) Use of alkylphosphocholines in combination with antitumor medicaments
CA2436332A1 (en) Use of alkylphosphocholines in combination with antitumor medications for the treatment of benign and malignant oncoses in humans and mammals
HK1080751B (en) Use of alkyl phosphocholines in combination with antitumor medicaments

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired